R
Robert A. Redd
Researcher at Harvard University
Publications - 51
Citations - 4194
Robert A. Redd is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 22, co-authored 23 publications receiving 2731 citations. Previous affiliations of Robert A. Redd include Fred Hutchinson Cancer Research Center & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy,Chip Stewart,Andrew Dunford,Jaegil Kim,Atanas Kamburov,Robert A. Redd,Michael S. Lawrence,Michael S. Lawrence,Margaretha G.M. Roemer,Amy Li,Marita Ziepert,Annette M. Staiger,Annette M. Staiger,Jeremiah Wala,Matthew D. Ducar,Ignaty Leshchiner,Ester Rheinbay,Amaro Taylor-Weiner,Caroline A. Coughlin,Julian M. Hess,Chandra Sekhar Pedamallu,Dimitri Livitz,Daniel Rosebrock,Mara Rosenberg,Adam Tracy,Heike Horn,Paul Van Hummelen,Andrew L. Feldman,Brian K. Link,Anne J. Novak,James R. Cerhan,Thomas M. Habermann,Reiner Siebert,Andreas Rosenwald,Aaron R. Thorner,Matthew Meyerson,Matthew Meyerson,Todd R. Golub,Todd R. Golub,Rameen Beroukhim,Rameen Beroukhim,Gerald Wulf,German Ott,Scott J. Rodig,Scott J. Rodig,Stefano Monti,Donna Neuberg,Markus Loeffler,Michael Pfreundschuh,Lorenz Trümper,Gad Getz,Gad Getz,Margaret A. Shipp +52 more
TL;DR: A comprehensive genetic analysis of 304 primary DLBCLs identified low-frequency alterations, captured recurrent mutations, somatic copy number alterations, and structural variants, and defined coordinate signatures in patients with available outcome data to provide a roadmap for an actionableDLBCL classification.
Journal ArticleDOI
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Margaretha G.M. Roemer,Ranjana H. Advani,Azra H. Ligon,Yasodha Natkunam,Robert A. Redd,Heather Homer,Courtney Connelly,Heather Sun,Sarah E. Daadi,Gordon J. Freeman,Philippe Armand,Bjoern Chapuy,Daphne de Jong,Richard T. Hoppe,Donna Neuberg,Scott J. Rodig,Margaret A. Shipp +16 more
TL;DR: There was an association between PD-L1 protein expression and relative genetic alterations in this series and further analyses of 9p24.1 alterations in patients treated with standard cHL induction regimens or checkpoint blockade are warranted.
Journal ArticleDOI
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.
R. Coleman Lindsley,Wael Saber,Brenton G. Mar,Robert A. Redd,Tao Wang,Michael D. Haagenson,Peter V. Grauman,Zhen-Huan Hu,Stephen R. Spellman,Stephanie J. Lee,Michael R. Verneris,Katharine C. Hsu,Katharina Fleischhauer,Corey Cutler,Joseph H. Antin,Donna Neuberg,Benjamin L. Ebert +16 more
TL;DR: Genetic profiling revealed that molecular subgroups of patients undergoing allogeneic hematopoietic stem‐cell transplantation for MDS may inform prognostic stratification and the selection of conditioning regimen.
Journal ArticleDOI
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
Margaretha G.M. Roemer,Margaretha G.M. Roemer,Robert A. Redd,Fathima Zumla Cader,Christine Pak,Sara Abdelrahman,Jing Ouyang,Stephanie Sasse,Anas Younes,Michelle A. Fanale,Armando Santoro,Pier Luigi Zinzani,John M. Timmerman,Graham P. Collins,Radhakrishnan Ramchandren,Jonathon B. Cohen,Jan de Boer,John Kuruvilla,Kerry J. Savage,Marek Trneny,Stephen M. Ansell,Kazunobu Kato,Benedetto Farsaci,Anne Sumbul,Philippe Armand,Donna Neuberg,Geraldine S. Pinkus,Azra H. Ligon,Scott J. Rodig,Margaret A. Shipp +29 more
TL;DR: Genetically driven PD-L1 expression and MHC class II positivity on HRS cells are potential predictors of favorable outcome after PD-1 blockade.
Journal ArticleDOI
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma
Christopher D. Carey,Christopher D. Carey,Daniel Gusenleitner,Mikel Lipschitz,Margaretha G.M. Roemer,Margaretha G.M. Roemer,Edward C. Stack,Evisa Gjini,Xihao Hu,Robert A. Redd,Gordon J. Freeman,Donna Neuberg,F. Stephen Hodi,Xiaole Shirley Liu,Margaret A. Shipp,Scott J. Rodig +15 more
TL;DR: A unique topology of cHL is defined in which PD-L1+ TAMs surround HRS cells and implicate CD4+ T cells as a target of PD-1 blockade.